Communiqués ABVC BioPharma, Inc.

Actions

ABVC

US00091F3047

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 20/08/2026			Varia. 5j.	Varia. 1 janv.
0,8899 ^USD	-4,97%		-7,24%	-58,22%

12/08	ABVC BioPharma, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
18/05	ABVC BioPharma, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

01/09/25	ABVC BioPharma Receives $450,000 in Licensing Payments from OncoX BioPharma in Q3 2025	AQ
19/12/24	ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21	AQ
11/12/24	ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners	AQ
14/11/24	ABVC BioPharma : Reports Q3 2024 Financial Results and Operational Milestones Form 8 K	PU
14/11/24	ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones	AQ
22/10/24	ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners	AQ
15/08/24	ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements	AQ
15/08/24	ABVC BioPharma : Reports Strong Q2 2024 Financial Results and Strategic Achievements Form 8 K	PU
02/07/24	ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals	AQ
24/05/24	Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M - Form 8-K	PU
15/05/24	Promising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M - Form 8-K	PU
09/05/24	Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	AQ
09/05/24	Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - Form 8-K	PU
18/04/24	AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share	AQ
17/04/24	ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	AQ
10/04/24	ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M	AQ
26/03/24	ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M	AQ
21/03/24	AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars	AQ
19/03/24	ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine	AQ
14/03/24	ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update	AQ
14/03/24	ABVC BioPharma : Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - Form 8-K	PU
15/02/24	ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues	AQ
12/02/24	ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)	AQ
08/02/24	ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share	AQ
03/01/24	ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees	AQ